Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/03/14 17:40:04」(JST)

Enocitabine (INN, marketed under the brand name Sunrabin) is a nucleoside analog used as chemotherapy.

Sunrabin contains the emulsifier HCO-60, which can cause allergic reactions.^[1]

References

^ Tatetsu H, Asou N, Nakamura M, et al. (July 2003). "[Allergic reaction against an emulsifier, HCO-60, contained in multamin and enocitabine]" (in Japanese). Rinsho Ketsueki 44 (7): 471–3. PMID 12931567.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

Terui Y.
Nihon rinsho. Japanese journal of clinical medicine.Nihon Rinsho.2015 Feb;73 Suppl 2:159-61.
PMID 25831743

Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status.

Yoon JH1, Cho BS, Kim HJ, Kim JH, Shin SH, Yahng SA, Lee SE, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW.
American journal of hematology.Am J Hematol.2013 Dec;88(12):1074-81. doi: 10.1002/ajh.23576. Epub 2013 Sep 12.
Several criteria to define fitness for induction chemotherapy in elderly acute myeloid leukemia (AML) have been proposed; however, no studies have reported outcomes according to the application of a risk-adapted approach. We treated 256 consecutive patients with elderly AML (≥60 years) with a risk
PMID 23983148

Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia.

Shimizu H1, Saitoh T, Hatsumi N, Takada S, Handa H, Jimbo T, Sakura T, Miyawaki S, Nojima Y.
Leukemia research.Leuk Res.2013 Nov;37(11):1477-81. doi: 10.1016/j.leukres.2013.08.017. Epub 2013 Sep 5.
Although studies have demonstrated a high prevalence of extramedullary (EM) relapse after allogeneic stem cell transplantation (allo-SCT) in patients with acute myeloid leukemia (AML), the prevalence of EM relapse has not been compared with that after chemotherapy. This study investigated the preval
PMID 24054717

Novel Drug Delivery System Using Autologous Fibrin Glue : Release Properties of Anti-cancer Drugs

YOSHIDA Hisahiro,YAMAOKA Yasuhiro,SHINOYAMA Mizuya,KAMIYA Akira
Biological & pharmaceutical bulletin 23(3), 371-374, 2000-03-01
… However, enocitabine was gradually released from glue with aprotinin although quickly released from that without. …
NAID 110003639978

阪本たけみ,栗山茂樹,吉川雅章,増井一弘,吉川正英,森村昌史,松為裕二,北方一成,小林洋三,岡本新悟,福井博
肝臓 37(9), 507-512, 1996-09-25
… She was diagnosed as acute myelocytic leukemia (M2 according to the FAB classification) by specimens of bone marrow puncture, and treated with BHAC-DMP (enocitabine, daunorubicin, mercaptopurine, prednisolone) regimen. …
NAID 10005571580

リンク元

Enocitabine
Systematic (IUPAC) name
	N-[1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]docosanamide
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	?
Legal status	℞ Prescription only
Routes	IV
Identifiers
CAS number	55726-47-1
ATC code	None
PubChem	CID 71734
ChemSpider	64778
UNII	9YVR68W306
KEGG	D01633
Chemical data
Formula	C31H55N3O6
Mol. mass	565.78 g/mol
	SMILES O=C(N/C/1=N/C(=O)N(\C=C\1)[C@@H]2O[C@@H]([C@@H](O)[C@@H]2O)CO)CCCCCCCCCCCCCCCCCCCCC;
	InChI InChI=1S/C31H55N3O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27(36)32-26-22-23-34(31(39)33-26)30-29(38)28(37)25(24-35)40-30/h22-23,25,28-30,35,37-38H,2-21,24H2,1H3,(H,32,33,36,39)/t25-,28-,29+,30-/m1/s1; Key:SAMRUMKYXPVKPA-VFKOLLTISA-N ;
(what is this?) (verify);